
ICU Medical, Inc.
ICUINASDAQHealthcareMedical - Instruments & Supplies
Previous close
$182.84
+$0.31 · +0.17%
ICUI company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
58
Fair Value
Momentum
60
Neutral
Sentiment
68
Bullish
Risk resilience
70
Moderate Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion therapy encompasses: Needlefree Connectors: Such as the MicroClave, MicroClave Clear, and NanoClave brands. Catheter Maintenance & Disinfection: Including Neutron patency devices and SwabCap/SwabTip disinfecting caps. Hemodialysis Solutions: Like Tego connectors and ClearGuard HD antimicrobial caps. Hazardous Drug Handling: With closed system transfer devices (ChemoClave, ChemoLock) and the Diana compounding system for safe preparation. They also provide a comprehensive range of intravenous (IV) solutions, diluents, and irrigation fluids, available in diverse packaging options like flexible containers and pour bottles. These include common formulations such as sodium chloride, dextrose, balanced electrolytes, lactated ringer's, mannitol, and sterile water, alongside specialized irrigation solutions like acetic acid and glycine. In medication management, ICU Medical offers sophisticated infusion pumps, including the Plum 360 and LifeCare PCA brands. Its advanced ICU Medical MedNet software enhances medication safety by integrating smart pumps with hospital electronic health records (EHRs), asset tracking, and alarm notification platforms. Accompanying professional services are also provided. For critical care environments, their portfolio features: Hemodynamic Monitoring: Systems like Cogent 2-in-1 and CardioFlo. Cardiac Output & Oximetry: TDQ, OptiQ, and TriOx catheters. Blood Pressure Transducers: Such as Transpac. Blood Sampling Systems: Including the SafeSet closed blood sampling and conservation systems. The company distributes its products to a wide spectrum of healthcare providers, including acute care hospitals, wholesalers, ambulatory clinics, and various alternate site facilities such as outpatient clinics, home healthcare services, and long-term care centers. Established in 1984, ICU Medical maintains its headquarters in San Clemente, California.
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Vivek Jain
- Listed since
- Mar 31, 1992
- Employees
- 13,000
Market position
Day range
Current $182.84
52-week range
Current $182.84
- Open
- $182.15
- Previous close
- $182.53
- Volume
- 182.32K
- 0.6× average
- Average volume
- 305.94K
- Average daily volume
- Market cap
- 4.57B USD
- Beta
- 0.75
- Market reference 1
- 50-day average
- $160.63
- +13.82% above average
- 200-day average
- $143.66
- +27.27% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 4.6B USD
- P/E (TTM)
- 152.37×
- P/B (TTM)
- 2.12×
- P/S (TTM)
- 2.12×
- EV / EBITDA
- 14.09×
- Earnings yield
- 0.02%
- Free cash flow yield
- 2.61%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 37.56%
- Operating margin
- 5.04%
- Net margin
- 1.39%
- Return on equity
- 0.03%
- Return on assets
- 0.02%
- Return on invested capital
- 0.69%
Financial health
- Debt / equity
- 0.59×
- Current ratio
- 2.36×
- Altman Z-score
- 2.56
- Piotroski F-score
- 6 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.23B USD | 2.38B USD | 2.26B USD | 2.28B USD | 1.32B USD |
| Cost of goods sold | 1.41B USD | 1.56B USD | 1.52B USD | 1.58B USD | 824.82M USD |
| Gross profit | 819.66M USD | 824.78M USD | 739.87M USD | 697.76M USD | 491.49M USD |
| Research and development | 87.5M USD | 88.62M USD | 85.34M USD | 92.98M USD | 47.5M USD |
| Selling, general, and administrative | 625.21M USD | 638.76M USD | 606.69M USD | 608.35M USD | 302.58M USD |
| Operating expenses | 712.71M USD | 781.82M USD | 717.05M USD | 740.66M USD | 368.25M USD |
| Interest income | 10.31M USD | 10.79M USD | 7.51M USD | 4.43M USD | 2.84M USD |
| Interest expense | 105.38M USD | 106.54M USD | 102.73M USD | 70.81M USD | 858K USD |
| Depreciation and amortization | 217.99M USD | 2.44M USD | 228.77M USD | 235.15M USD | 99.29M USD |
| Operating income | 106.95M USD | 42.96M USD | 22.83M USD | −42.9M USD | 123.25M USD |
| Net income | 732K USD | −117.69M USD | −29.66M USD | −74.29M USD | 103.14M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 100%
- 11 beats, 0 misses, 0 met estimates
- Average EPS surprise
- +32.03%
- 11 comparable reports
- Latest EPS result
- 2.37
- Estimate 1.91 · Beat by 24.08%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$186.4
1.95% upsideRating distribution
12 ratingsRecent analyst actions
ICUI news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Mar 18, 2002 | 3:2 | — | — |
Stock split | Apr 1, 1993 | 3:2 | — | — |
Effective Mar 18, 2002
3:2
Effective Apr 1, 1993
3:2
ICUI peers
ETFs holding ICUI
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR277.67M0.25%111.19B USD0.06%$147.31+0.64%
Vanguard Morningstar Total Stock Market ETFVTI134.05M0.01%2.3T USD0.03%$378.24+0.44%
iShares Russell 2000 ETFIWM113.99M0.14%81.62B USD0.19%$299.96+0.77%
Vanguard Morningstar Small-Cap ETFVB96.89M0.05%183.4B USD0.03%$304.76+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR61.5M0.09%68.3B USD0.05%$249.18+0.68%
Vanguard Extended Market ETFVXF48.5M0.05%93.7B USD0.05%$245.53+0.82%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM42.85M0.25%17.03B USD0.03%$57.28+0.61%
iShares Russell 2000 Value ETFIWN42.2M0.29%14.66B USD0.24%$224.81+0.45%
iShares Core S&P Small-Cap ETFIJR- Market value
- 277.67M
- Weight
- 0.25%
- AUM
- 111.19B USD
- Expense ratio
- 0.06%
- Price / 1D
- $147.31+0.64%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 134.05M
- Weight
- 0.01%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
iShares Russell 2000 ETFIWM- Market value
- 113.99M
- Weight
- 0.14%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
Vanguard Morningstar Small-Cap ETFVB- Market value
- 96.89M
- Weight
- 0.05%
- AUM
- 183.4B USD
- Expense ratio
- 0.03%
- Price / 1D
- $304.76+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR- Market value
- 61.5M
- Weight
- 0.09%
- AUM
- 68.3B USD
- Expense ratio
- 0.05%
- Price / 1D
- $249.18+0.68%
Vanguard Extended Market ETFVXF- Market value
- 48.5M
- Weight
- 0.05%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM- Market value
- 42.85M
- Weight
- 0.25%
- AUM
- 17.03B USD
- Expense ratio
- 0.03%
- Price / 1D
- $57.28+0.61%
iShares Russell 2000 Value ETFIWN- Market value
- 42.2M
- Weight
- 0.29%
- AUM
- 14.66B USD
- Expense ratio
- 0.24%
- Price / 1D
- $224.81+0.45%
Continue in GoAI
Research ICUIresearch.disclaimer











